Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction

Abstract

Arsenic trioxide is a new and investigational agent for the treatment of relapsed or refractory acute promyelocytic leukemia (APL). Leukocytosis has been commonly noted with its use; however, this side effect usually resolves spontaneously and is generally not treated. To date, no deaths have been